AU2007309570B2 - Substituted imidazoles as bombesin receptor subtype-3 modulators - Google Patents

Substituted imidazoles as bombesin receptor subtype-3 modulators Download PDF

Info

Publication number
AU2007309570B2
AU2007309570B2 AU2007309570A AU2007309570A AU2007309570B2 AU 2007309570 B2 AU2007309570 B2 AU 2007309570B2 AU 2007309570 A AU2007309570 A AU 2007309570A AU 2007309570 A AU2007309570 A AU 2007309570A AU 2007309570 B2 AU2007309570 B2 AU 2007309570B2
Authority
AU
Australia
Prior art keywords
alkyl
substituted
unsubstituted
group
pct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2007309570A
Other languages
English (en)
Other versions
AU2007309570A1 (en
Inventor
David Chen
Christopher L. Franklin
Peter R. Guzzo
Linus S. Lin
Michael M.-C. Lo
Ravi P. Nargund
Iyassu K. Sebhat
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme Ltd
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme Ltd, Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme Ltd
Publication of AU2007309570A1 publication Critical patent/AU2007309570A1/en
Assigned to MERCK SHARP & DOHME CORP. reassignment MERCK SHARP & DOHME CORP. Alteration of Name(s) of Applicant(s) under S113 Assignors: MERCK & CO., INC.
Application granted granted Critical
Publication of AU2007309570B2 publication Critical patent/AU2007309570B2/en
Assigned to MERCK SHARP & DOHME CORP. reassignment MERCK SHARP & DOHME CORP. Request to Amend Deed and Register Assignors: MERCK SHARP & DOHME CORP.
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2007309570A 2006-10-20 2007-10-16 Substituted imidazoles as bombesin receptor subtype-3 modulators Ceased AU2007309570B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85319306P 2006-10-20 2006-10-20
US60/853,193 2006-10-20
PCT/US2007/022087 WO2008051406A2 (en) 2006-10-20 2007-10-16 Substituted imidazoles as bombesin receptor subtype-3 modulators

Publications (2)

Publication Number Publication Date
AU2007309570A1 AU2007309570A1 (en) 2008-05-02
AU2007309570B2 true AU2007309570B2 (en) 2012-07-12

Family

ID=39325111

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007309570A Ceased AU2007309570B2 (en) 2006-10-20 2007-10-16 Substituted imidazoles as bombesin receptor subtype-3 modulators

Country Status (13)

Country Link
US (1) US8193228B2 (enExample)
EP (1) EP2091937A2 (enExample)
JP (1) JP5047299B2 (enExample)
KR (1) KR20090064458A (enExample)
CN (1) CN101528730A (enExample)
AU (1) AU2007309570B2 (enExample)
BR (1) BRPI0717976A2 (enExample)
CA (1) CA2666310C (enExample)
IL (1) IL198004A0 (enExample)
MX (1) MX2009004112A (enExample)
NO (1) NO20091957L (enExample)
RU (1) RU2009118935A (enExample)
WO (1) WO2008051406A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008051404A2 (en) 2006-10-20 2008-05-02 Merck & Co., Inc. Substituted imidazoles as bombesin receptor subtype-3 modulators
CA2667003A1 (en) 2006-10-20 2008-05-02 Merck & Co., Inc. Substituted imidazoles as bombesin receptor subtype-3 modulators
WO2009123164A1 (ja) * 2008-04-02 2009-10-08 塩野義製薬株式会社 血管内皮リパーゼ阻害活性を有するヘテロ環誘導体
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013135674A1 (en) * 2012-03-12 2013-09-19 Syngenta Participations Ag Insecticidal 2-aryl-acetamide compounds
CN103497159B (zh) * 2013-09-18 2015-08-12 苏州岚云医药科技有限公司 1,2-二取代-5-磺酰基咪唑类化合物的制备方法
KR20240144424A (ko) 2015-10-23 2024-10-02 나비토르 파마슈티칼스 인코포레이티드 세스트린-gator2 상호작용의 조절제 및 이의 용도
CN116370448A (zh) 2017-04-26 2023-07-04 纳维托制药有限公司 Sestrin-gator2相互作用的调节剂及其用途
CA3117336A1 (en) 2018-10-24 2020-04-30 Navitor Pharmaceuticals, Inc. Polymorphs of (s)-2-amino-5,5-difluoro-4,4-dimethylpentanoic acid for use in modulating mtorc1
CA3156436A1 (en) 2019-11-01 2021-05-06 Steven LEVENTER Methods of treatment using an mtorc1 modulator

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004071447A2 (en) * 2003-02-12 2004-08-26 Transtech Pharma Inc. Substituted azole derivatives as therapeutic agents
US20050187277A1 (en) * 2004-02-12 2005-08-25 Mjalli Adnan M. Substituted azole derivatives, compositions, and methods of use

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4962117A (en) * 1987-11-25 1990-10-09 Merck Frosst Canada, Inc. Heterazole dialkanoic acids
WO1993017681A1 (en) 1992-03-02 1993-09-16 Abbott Laboratories Angiotensin ii receptor antagonists
JPH07243068A (ja) 1994-03-08 1995-09-19 Murata:Kk 金属表面の電解処理方法
JP2000511883A (ja) 1996-04-19 2000-09-12 ノボ ノルディスク アクティーゼルスカブ ホスホチロシン認識ユニットを有する分子のモジュレーター
KR20000062284A (ko) 1996-12-23 2000-10-25 블레어 큐. 퍼거슨 인자 Ｘａ 억제제로서의 질소 함유 헤테로방향족 화합물
JPH11217348A (ja) 1997-10-15 1999-08-10 Otsuka Pharmaceut Co Ltd フルオレノン誘導体の製造法
BR9813835A (pt) 1997-12-22 2000-10-10 Du Pont Pharm Co Composto, composição farmacêutica e método de tratamento ou prevenção de uma desordem tromboembólica
AR024077A1 (es) * 1999-05-25 2002-09-04 Smithkline Beecham Corp Compuestos antibacterianos
JP3842976B2 (ja) * 2000-03-17 2006-11-08 富士通株式会社 分布帰還型半導体レーザとその製造方法
AU2001277723A1 (en) 2000-08-11 2002-02-25 Nippon Chemiphar Co., Ltd. Ppardelta activators
WO2002098840A1 (en) 2001-06-04 2002-12-12 Eisai Co., Ltd. Carboxylic acid derivative and medicine comprising salt or ester of the same
EP1424330B1 (en) 2001-08-10 2011-09-28 Nippon Chemiphar Co., Ltd. Activator for peroxisome proliferator-responsive receptor delta
WO2003063781A2 (en) * 2002-01-29 2003-08-07 Merck & Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
JP2003321455A (ja) 2002-02-28 2003-11-11 Nissan Chem Ind Ltd ｏ−置換ベンゾイル化合物及びこれを有効成分とする除草剤
DE10224844A1 (de) 2002-06-05 2004-01-08 Solvay Pharmaceuticals Gmbh Nicht-peptidische BRS-3-Agonisten
AU2003281039A1 (en) 2002-07-10 2004-02-02 Sumitomo Pharmaceuticals Co., Ltd. Imidazole derivative
JP2006506366A (ja) * 2002-10-18 2006-02-23 ファイザー・プロダクツ・インク カンナビノイド受容体リガンドおよびその使用方法
DE60330997D1 (de) 2002-11-19 2010-03-04 Galderma Res & Dev Biaromatische verbindungen die ppar-gamma rezeptoren aktivieren und deren anwendungen in kosmetischen oder pharmazeutischen zusammensetzungen
EP1567509A2 (en) 2002-11-25 2005-08-31 Galderma Research & Development, S.N.C. Biphenyl compounds which activate ppar-gamma type receptors, and use thereof in cosmetic or pharmaceutical compositions
CA2509565A1 (en) 2002-12-20 2004-07-15 Pharmacia Corporation Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds
WO2004071509A1 (ja) 2003-02-12 2004-08-26 Nippon Chemiphar Co., Ltd. オリゴデンドロサイト分化促進剤
US20040167188A1 (en) * 2003-02-14 2004-08-26 Zhili Xin Protein-tyrosine phosphatase inhibitors and uses thereof
MXPA05012281A (es) 2003-05-14 2006-05-19 Torreypines Therapeutics Inc Compuestos y uso de los mismos en la modulacion beta amiloide.
WO2005035551A2 (en) 2003-10-08 2005-04-21 Incyte Corporation Inhibitors of proteins that bind phosphorylated molecules
EP1689716A1 (en) * 2003-12-04 2006-08-16 Wyeth Biaryl sulfonamides and methods for using same
GB0328796D0 (en) 2003-12-12 2004-01-14 Biofocus Plc Compounds which interact with the G-protein coupled receptor family
AU2004299456B2 (en) 2003-12-17 2010-10-07 Merck Sharp & Dohme Corp. (3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonists
GB0403578D0 (en) 2004-02-18 2004-03-24 Biofocus Discovery Ltd Compounds which interact with the G-protein coupled receptor family
US7618981B2 (en) 2004-05-06 2009-11-17 Cytokinetics, Inc. Imidazopyridinyl-benzamide anti-cancer agents
CA2667003A1 (en) 2006-10-20 2008-05-02 Merck & Co., Inc. Substituted imidazoles as bombesin receptor subtype-3 modulators
WO2008051404A2 (en) 2006-10-20 2008-05-02 Merck & Co., Inc. Substituted imidazoles as bombesin receptor subtype-3 modulators

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004071447A2 (en) * 2003-02-12 2004-08-26 Transtech Pharma Inc. Substituted azole derivatives as therapeutic agents
US20050187277A1 (en) * 2004-02-12 2005-08-25 Mjalli Adnan M. Substituted azole derivatives, compositions, and methods of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BRESLOW, R. ET AL. JACS, (1983) 105(16): 5337-5342 *

Also Published As

Publication number Publication date
JP2010506919A (ja) 2010-03-04
AU2007309570A1 (en) 2008-05-02
NO20091957L (no) 2009-07-17
CN101528730A (zh) 2009-09-09
WO2008051406A3 (en) 2008-07-24
EP2091937A2 (en) 2009-08-26
US8193228B2 (en) 2012-06-05
CA2666310C (en) 2012-07-31
BRPI0717976A2 (pt) 2013-11-12
US20100022598A1 (en) 2010-01-28
RU2009118935A (ru) 2010-11-27
KR20090064458A (ko) 2009-06-18
JP5047299B2 (ja) 2012-10-10
WO2008051406A2 (en) 2008-05-02
MX2009004112A (es) 2009-05-11
IL198004A0 (en) 2009-12-24
CA2666310A1 (en) 2008-05-02

Similar Documents

Publication Publication Date Title
AU2007309570B2 (en) Substituted imidazoles as bombesin receptor subtype-3 modulators
AU2007238771B2 (en) Substituted imidazole 4-carboxamides as cholecystokinin-1 receptor modulators
AU2007332867B2 (en) Substituted diazepine sulfonamides as bombesin receptor subtype-3 modulators
AU2007238744A1 (en) Substituted imidazole 4-carboxamides as cholecystokinin-1 receptor modulators
AU2007238804A1 (en) Substituted imidazole 4-carboxamides as cholecystokinin-1 receptor modulators
US8183275B2 (en) Substituted imidazoles as bombesin receptor subtype-3 modulators
US8318767B2 (en) Substituted imidazoles as bombesin receptor subtype-3 modulators
AU2006320797A1 (en) Heterocycle-substituted 3-alkyl azetidine derivatives

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired